Get started
Author

John McGlothlin

Observed names: JOHN MCGLOTHLIN, MD John D. McGlothlin,
ORCID: 0000-0001-9471-479X
Observed ORCID: 0000-0001-9471-479X
OpenAlex ID: A5012750422
Bortezomib and daratumumab in refractory autoimmune hemolytic anemia
2023 · John McGlothlin, Jithma Abeykoon, et al. · American Journal of Hematology · 8
PDF
Utilizing predictive modeling to identify patients at high risk of death from immune checkpoint inhibitor therapy-related pneumonitis.
2023 · Antonious Ziad Hazim, Jacob Tyler Shreve, et al. · Journal of Clinical Oncology · 1
PDF
Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
2022 · John McGlothlin, Jithma P. Abeykoon, et al. · Blood · 1
CDH6-high gastric cancers as exhibitors of a reproducible vascular–stromal, immune-excluded tumor microenvironment.
2026 · John McGlothlin, Ruthvik Edara, et al. · Journal of Clinical Oncology
CDH17 expression and tumor microenvironment composition in gastric cancer.
2026 · Ammanuel Taye, Ruthvik Edara, et al. · Journal of Clinical Oncology
Transformation of low-intermediate grade neuroendocrine tumors into high grade morphology
2023 · MD John D. McGlothlin,, MD Saam Dilmaghani,, et al. · Endocrine Abstracts
Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Effect on Pulmonary Function Testing
2023 · IRENE RIESTRA GUIANCE, ANTONIOUS HAZIM, et al. · CHEST Journal
PDF
Works count: 7
Citation count: 10
H-index: 1
I10-index:
Year
Topic
Type